High-dose biotin in multiple sclerosis: the end of the road

@article{Motte2020HighdoseBI,
  title={High-dose biotin in multiple sclerosis: the end of the road},
  author={Jeremias Motte and Ralf Gold},
  journal={The Lancet Neurology},
  year={2020},
  volume={19},
  pages={965-966}
}
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
TLDR
The evidence that reactive microglia and macrophages upregulate pro-inflammatory genes and downregulate homeostatic genes, that may promote neurodegeneration in progressive MS are reviewed.
Hormone Immunoassay Interference: A 2021 Update
TLDR
This review focuses on the analytical interferences encountered in daily practice and possible solutions for their detection or elimination.
CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease
TLDR
High-dose biotin and thiamine supplementation improved radiological, motor, and neuropathological phenotypes in HD mice, suggesting that the treatment might be useful for patients with HD and revealing an easily implementable therapy that might benefit patients withHD.

References

SHOWING 1-9 OF 9 REFERENCES
The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis
TLDR
HDB appeared well-tolerated and safe, and there were 11 cases of apparent hyperthyroidism (low thyroid-stimulating hormone) in patients taking HDB, which was determined to be due to biotin interference with laboratory tests that utilize biotinylated antibodies.
Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin
TLDR
The case of a 41-year-old patient suffering from primary progressive MS who presented after 16 months of treatment with high doses of biotin with worsening of his Expanding Disability Status Scale (EDSS) score and the appearance of a symptomatic new T2 pseudo-tumoural lesion on brain magnetic resonance imaging (MRI), suggestive of tardive inflammatory reactivation possibly due to the biotin is reported.
Effects of open-label placebo on pain, functional disability and spine mobility in chronic back pain patients: a randomized controlled trial.
TLDR
It is demonstrated that a 3-week open-label placebo treatment is safe, well tolerated and reduces pain, disability and depressive symptoms in chronic back pain.
Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin
TLDR
A transient myopathy resembling multiple acyl-coenzyme A dehydrogenase deficiency (MADD) or riboflavin transporter defects, reversible upon biotin withdrawal is reported, which is similar to that seen in patients with progressive multiple sclerosis in a small controlled trial.
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
TLDR
In a double-blind, placebo-controlled study, MD1003 achieves sustained reversal of MS-related disability in a subset of patients with progressive MS and is well tolerated.
High dose biotin as treatment for progressive multiple sclerosis.
High doses of biotin in chronic progressive multiple sclerosis: a pilot study.